个人简历
1998年毕业于福建医科大学临床医学专业获医学学士学位、2001年毕业于福建医科大学药理学专业获硕士学位、2007年毕业于福建医科大学药理学专业获博士学位。曾赴美国南卡罗莱那医科大学和美国阿肯色州医科大学及进行博士后研究。现任福建医科大学药理系常务副主任、新药研究所副所长，2011年获得福建省自然科学基金杰出青年项目，同年入选福建省高等学校新世纪优秀人才支持计划。
研究领域
一直从事抗肿瘤药物药理，主要研究DNA修复的分子机制和靶向小分子药物清除肿瘤细胞及其干细胞应用基础研究。
近期论文
1.Wu L., *Xu J., Zhang K., Lin Q., Huang X, Wen C., *Chen Y. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008;22: 1402-1409.（IF：8.931） 2.*Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y, Wu Y, *Chen Y, and *Xu J. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.Clin Cancer Res 2015; 21(4); 833–43. （IF：8.722）（*通讯作者） 3.Wu L, Shao L, An N, Wang J, Pazhanisamy S, Feng W, Hauer-Jensen M, Miyamoto S, * Zhou D. IKKβ regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS One. 2011 Apr 7;6(4):e18447.（IF：4.092） 4.*Wu L, Chen X, Huang L, Tian J, Ke F, Xu J, Chen Y, * Zheng M. A novobiocin derivative, XN4, inhibits the proliferation of chronic myeloid leukemia cells by inducing oxidative DNA damage. PLoS One 2015;10(4): e0123314. （IF：3.534）（*通讯作者） 5.*Wu L, Wu Y, Chen R, Liu Y, Huang L, Zheng Z, Chen Y, *Xu J. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.Acta Pharmacol Sin. 2014 Mar;35(3):401-9. （IF：2.354）（*通讯作者） 6.Wu L, Shao L, Li M, Zheng J, Wang J, Feng W, Chang J, Wang Y, Hauer-Jensen M, *Zhou D. BMS-345541 sensitizes MCF-7 breast cancer cells to ionizing radiation by selective inhibition of homologous recombinational repair of DNA double-strand breaks. Radiat Res. 2013 Feb;179(2):160-70.（IF：2.932） 7.Wu L, Xu J, Huang X, Zhang K, Wen C, Chen Y. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacologica Sinica 2006;27:694-699.（IF：2.911） 8.Wu L, Xu J, Wu G, Wen C, Chen Y. Inhibitory effect of curcumin on proliferation of K562 cells involves down-regulation of p210(bcr/abl)-initiated Ras signal transduction pathway，Acta Pharmacologica Sinica 2003；24：1155-1160. （IF：2.911） 9.Shao L, Wu L, Zhou D. Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor κB kinase. Transl Cancer Res. 2012 Aug;1(2):100-108.Pubmed 10.Zhang, Kunzhong, Xu, Jianhua, Huang, Xiuwang, Wu, Lixian, Wen, Caixia, Hu, Yingying, Su, Yu, Chen,Yuanzhong, Zhang, Zhiqiang ，Trichosanthin down-regulated p210(Bcr-Abl) and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562 ，Cancer Chemotherapy and Pharmacology 2007;60:581-587.（IF：2. 543） 11.Zhang, Kun-zhong, Xu, Jian-hua, Huang, Xiu-wang, Wu, Li-xian, Su, Yu, Chen,Yuan-zhong. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacologica Sinica 2007 ;28: 105-110. （IF：2.911）
